The BioCentury Show

Hosted by BioCentury

Business Science

Website RSS feed LinkedIn YouTube

Episodes

Latest episode

Oct 2026

Language

EN-US

About the show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast .

Listen to episodes

60 recent

October 30, 2026Episode 12333 min

Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process

On this edition of The BioCentury Show , Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its investment decisions. Muijrers explains how council input steered Gilde away from one deal and toward another, diagnostics company Karius, and why he argues patient perspectives belong alongside physician input in diligence and development strategy. He also describes the frameworks Gilde has developed for engaging patient organizations, and why he urges other investors to adopt them as a pre-competitive practice. This episode of The BioCentury Show is brought to you by Tigermed . View full story: https://www.biocentury.com/article/661356 #PatientEngagement #BiotechInvesting #ImpactInvesting #VentureCapital #MarketAccess 0:00 Introduction 2:00 Creating Gilde's Impact Council 7:32 Advisors' Impact on Investing 16:42 Gilde's Approach to Patient Engagement 23:50 Where Patient Input Fits in Decision-making 29:17 Why Other Investors Should Engage

October 21, 2026Episode 12229 min

Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China

Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show , Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both in a single protocol can de-risk FDA acceptance while capturing China’s enrollment speed. Winterberger also discusses investigator-initiated trials in China, China’s new IIT regulations, and trial trends spanning bispecifics, ADCs, cell and gene therapies, and radiopharmaceuticals. This episode of The BioCentury Show is brought to you by Tigermed . View full story: https://www.biocentury.com/article/661260 #GlobalClinicalTrials #IITs #Oncology #ADCs #CRO 0:00 Introduction 1:17 Tigermed's Global Capabilities 2:59 Running Trials in China 7:05 Chinese Sponsors in the U.S. 16:42 IITs 22:28 Trends in Trial Design

October 17, 2026Episode 12137 min

Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi

Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once. View full story: https://www.biocentury.com/article/661194 #RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech 0:00 Introduction 1:09 Arrowhead's siRNA Platform 9:05 Solving for Extra-Hepatic Delivery 23:43 Redemplo's Future Growth 27:00 Obesity and Bispecific siRNA

October 2, 2026Episode 12038 min

Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces

Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars. View full story: https://www.biocentury.com/article/660963 #VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA 0:00 Introduction 1:19 Canaan's Strategy 11:34 Team Building 21:57 White Space 28:00 New Biotech Buyers 34:15 Biotech Founders

September 18, 2026Episode 11934 min

Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

On this edition of The BioCentury Show , Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets. Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway. View full story: https://www.biocentury.com/article/660824 #Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials 0:00 Introduction 1:22 New Fund & Founding 10:30 Alnylam Deal 17:14 Working with Big Caps 25:54 Biotech Risk 29:13 China

September 4, 2026Episode 11831 min

Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

On This Edition of The BioCentury Show , Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 - Getting to Drug Development 21:51 - Best AI Use Cases

August 21, 2026Episode 11729 min

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients. In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show , C-Path CEO and CSO Klaus Romero discusses how the principal bottleneck is no longer the ability to design therapies for individual patients but rather the absence of a standardized regulatory and development system that can translate one success into many. C-Path plans to bring companies, academics, patient groups, and regulators together to share data and address recurring development bottlenecks. View full story: https://www.biocentury.com/article/660583 #GeneticMedicines #RareDisease #DrugDevelopment #RegulatoryScience #ClinicalTrials 00:00 - Introduction 01:44 - Current Framework 07:01 - Process-based Regulation 13:57 - Overcoming Bottlenecks 20:28 - Use of AI 25:25 - Beyond Rare Diseases

August 7, 2026Episode 11632 min

Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech. View full story: https://www.biocentury.com/article/660408 #Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation 00:00 - Introduction 03:24 - Biotech Under Threat 10:38 - CEO Compensation 15:39 - Competing with China 22:08 - U.S. Policy Prescriptions 30:00 - Looking Ahead

July 23, 2026Episode 11540 min

Ep. 115 - Initiate's Owens on what it takes to be AI-native

As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show , Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model. Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients. View full story: https://www.biocentury.com/article/660203 #AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment 00:00 - Introduction 01:15 - Initiate Ventures' Thesis 07:04 - What Makes Founders Fundable 17:36 - Defining AI Native Healthcare 23:20 - Diagnostics & Evidence Generation 36:44 - Non-Invasive Fibrosis Testing

July 10, 2026Episode 11441 min

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show , Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he views AI at Roivant and more broadly in biopharma R&D, the science behind Roivant’s next most advanced program, Phase III anti-FcRN mAb imeroprubart and the lessons he’s taking from a “graduating class” of biotechs that have launched programs, like Alnylam and Argenx S.E. View full story: https://www.biocentury.com/article/660059 #DrugDevelopment #BiotechInnovation #Commercialization #ArtificialIntelligence #BiopharmaStrategy 00:00 - Introduction 00:42 - Roivant’s Evolution 09:19 - AI in R&D 17:48 - Lead Asset Brepocitinib 28:23 - Anti-FcRN mAb Imeroprubart 32:23 - China 37:55 - What’s Next for Roivant